文献速递治疗药物监测与药物基因组学

伊马替尼群体药代动力学模型在成人慢性髓性白血病患者中的外部评价

External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia.
PubMed 文献 · Br J Clin Pharmacol · 2021-11-26

Petain等提出的模型预测性能最佳,贝叶斯预测在第二次访视时显著改善预测性能,且两次不同访视的样本足以达到良好的个体预测性能。

要点

  • Petain等模型在预测偏差和精度上表现最佳
  • 贝叶斯预测在第二次访视时显著提升预测性能
  • 两次不同访视的伊马替尼样本即可满足个体预测需求

核心结论

  • 基于白种人群且包含α1-酸性糖蛋白的伊马替尼群体药代动力学模型在总体偏差和精度上表现最佳。
  • 贝叶斯预测在第二次访视时显著改善预测性能,两次不同访视的样本足以达到 adequate 的个体预测性能。

主要发现

  • Petain等提出的模型在研究人群中基于预测的诊断表现最佳。
  • 贝叶斯预测在第二次访视时预测性能显著改善。
  • 访视间变异有助于降低偏差并改善基于模型的个体预测。

临床怎么用

  • 临床可优先考虑Petain等模型用于成人慢性髓性白血病患者的伊马替尼个体化预测。
  • 采用贝叶斯预测时,建议至少收集两次不同访视的伊马替尼血药浓度样本以提高个体预测性能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Imatinib is considered the standard first-line treatment in newly diagnosed patients with chronic-phase myeloid leukaemia (CML). Several imatinib population pharmacokinetic (popPK) models have been developed. However, their predictive performance has not been well established when extrapolated to different populations. Therefore, this study aimed to perform an external evaluation of available imatinib popPK models developed mainly in adult patients, and to evaluate the improvement in individual model-based predictions through Bayesian forecasting computed by each model at different treatment occasions. METHODS: A literature review was conducted through PubMed and Scopus to identify popPK models. Therapeutic drug monitoring data collected in adult CML patients treated with imatinib was used for external evaluation, including prediction- and simulated-based diagnostics together with Bayesian forecasting analysis. RESULTS: Fourteen imatinib popPK studies were included for model-performance evaluation. A total of 99 imatinib samples were collected from 48 adult CML patients undergoing imatinib treatment with a minimum of one plasma concentration measured at steady-state between January 2016 and December 2020. The model proposed by Petain et al showed the best performance concerning prediction-based diagnostics in the studied population. Bayesian forecasting demonstrated a significant improvement in predictive performance at the second visit. Inter-occasion variability contributed to reducing bias and improving individual model-based predictions. CONCLUSIONS: Imatinib popPK studies developed in Caucasian subjects including α1-acid glycoprotein showed the best model performance in terms of overall bias and precision. Moreover, two imatinib samples from different visits appear sufficient to reach an adequate model-based individual prediction performance trough Bayesian forecasting.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Corral Alaejos Á, Zarzuelo Castañeda A, Jiménez Cabrera S, et al. External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia. Br J Clin Pharmacol. 2021. PMID: 34705297. doi:10.1111/bcp.15122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。